Molecular labs continue to gain ground with insurers. This summer, 8 more genetic assays received positive coverage decisions—4 from Medicare and 4 from private insurers. The winners included Genomic Health, CareDx, Myriad Genetics, Castle Biosciences, Interpace Diagnostics and NanoString Technologies. Here’s a rundown of the key details. The Medicare Approvals Four of the approvals came…
Reimbursement Trends: 8 Molecular Assays Score Big Coverage Wins from Medicare, Private Insurers
by Glenn S. Demby | Sep 29, 2017 | National Lab Reporter, News-nir, Reimbursement-nir